SATURDAY, April 6 (HealthDay News) -- A novel but preliminary
new treatment for ovarian cancer has apparently produced complete
remission for one patient with an advanced form of the disease,
researchers are reporting.
The promising results of a phase 1 clinical trial for the
immunotherapy approach also showed that seven other women had no
measurable disease at the end of the trial, the researchers
Their results are scheduled to be presented Saturday at the
American Association for Cancer Research's annual meeting in
Ovarian cancer is fairly rare -- an estimated 1.38 percent of
females born today will be diagnosed with the condition -- but it's
an especially deadly form of cancer because it is usually diagnosed
in an advanced stage.
The new treatment uses a personalized vaccine to try to teach
the body's immune system how to fight off tumors.
Researchers took bits of tumor and blood from women with stage 3
or 4 ovarian cancer and created individualized vaccines, said study
lead author Lana Kandalaft, director of clinical development and
operations at the Ovarian Cancer Research Center in the University
of Pennsylvania's Perelman School of Medicine.
"Each patient's tumor is unique like a fingerprint," she added. "We're trying to rewire the immune system to target the tumor."
Once the immune system has learned how to more effectively fight
the cancer, the researchers isolate immune cells called dendritic
cells, coax them to multiply, then put them back into the body to
The research is only in the first of three stages that are
required before drugs can be sold in the United States. The
first-phase studies aren't designed to determine if the drugs
actually work, but are instead supposed to analyze whether they're
This study, funded in part by the U.S. National Institutes of
Health, found signs of improvement in 19 out of 31 patients. All 19
developed an anti-tumor immune response. Of those, eight had no
measurable disease and are on maintenance vaccine therapy. And one
of the eight, whose cancer recurred several times, has been in
remission for 45 months, the study authors said.
The researchers added a further step for 11 patients who
responded to the vaccine treatment but still had residual disease.
They removed immune cells called T cells from patients' blood,
stimulated and expanded the cells in the laboratory, and then
reinjected them into the patients. Of the 11 patients, seven had
stable disease and one had a complete response, the investigators
Both treatments were given in conjunction with bevacizumab, a
drug that controls blood vessel growth.
Side effects were mild, Kandalaft said. As for cost, she
believes that it will be cheaper than some existing cancer drugs
that cost $75,000 to $100,000 for a regimen.
The next step is to continue research into the treatment, she
A second study being presented at the meeting focused on an
experimental drug to treat women whose ovarian cancer has developed
resistance to platinum-based chemotherapy. The cancer inevitably
gets worse in patients when chemotherapy no longer works.
The drug, being developed by the Genentech pharmaceutical
company, is designed to deliver a kind of poison to cancer cells
without being too toxic to the patient.
Researchers led by Dr. Joyce Liu, of the Dana-Farber Cancer
Institute and Harvard Medical School in Boston, found that five
patients out of 44 responded at least partially to the treatment.
However, many who took the treatment suffered from several types of
A researcher who was not involved in the studies said the
treatments all appear promising, although preliminary, and show how
medicine is moving toward alternatives to chemotherapy.
"This is where we have to start. This is the future," said Dr. Linda Duska, a gynecologist at the University of Virginia.
For more about
ovarian cancer, visit the U.S. National Library of Medicine.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.